Compare NKTR & RUN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NKTR | RUN |
|---|---|---|
| Founded | 1990 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.4B |
| IPO Year | 1996 | 2015 |
| Metric | NKTR | RUN |
|---|---|---|
| Price | $73.46 | $9.32 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 20 |
| Target Price | ★ $146.67 | $18.80 |
| AVG Volume (30 Days) | 601.3K | ★ 9.4M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 113.35 |
| EPS | N/A | ★ 1.04 |
| Revenue | $307,711,000.00 | ★ $858,578,000.00 |
| Revenue This Year | N/A | $2.81 |
| Revenue Next Year | N/A | $4.54 |
| P/E Ratio | ★ N/A | $9.42 |
| Revenue Growth | ★ 86.00 | 12.97 |
| 52 Week Low | $26.45 | $8.61 |
| 52 Week High | $109.00 | $22.44 |
| Indicator | NKTR | RUN |
|---|---|---|
| Relative Strength Index (RSI) | 61.38 | 41.65 |
| Support Level | $64.28 | $9.31 |
| Resistance Level | $78.81 | $11.19 |
| Average True Range (ATR) | 2.61 | 0.59 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 90.85 | 40.31 |
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
Sunrun is engaged in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems in the United States. The company acquires customers directly and through relationships with various solar and strategic partners. The solar systems are constructed by Sunrun or by Sunrun's partners and are owned by the company. Sunrun's customers typically enter into 20- to 25-year agreements to utilize its solar energy system. The company also sells solar energy systems and products, such as panels and racking, and solar leads generated to customers.